A basophil activation test above the positive cut-off confirms the
diagnosis of IgE-mediated allergy.
Basophil reactivity and basophil sensitivity decrease over the course
of allergen specific immunotherapy and EC50 (or CD-sens) seem to be
particularly important in reflecting the change in clinical allergen
threshold.
Omalizumab decreases basophil response to allergen as a consequence of
the decrease in IgE receptor density and circulating IgE.
|